Advertisement
ADPT vs GH
Which Stock Would AI Choose? Adaptive Biotechnologies (ADPT) vs. Guardant Health (GH) Stock Comparison
Key Takeaways
- Both ADPT and GH operate in the precision medicine and diagnostics space but target different segments of the healthcare market.
- Guardant Health has demonstrated stronger revenue growth momentum in recent quarters, driven by expanding adoption of its liquid biopsy (a non-invasive blood test used to detect cancer-related genetic mutations) tests.
- Adaptive Biotechnologies continues to advance its immune medicine platform, with key partnerships and minimal residual disease (MRD, referring to the small number of cancer cells remaining after treatment) testing as central growth catalysts.
- Market sentiment has diverged, with Guardant benefiting from clearer commercial pathways while Adaptive navigates a longer research-and-development cycle.
- Risk profiles differ meaningfully: ADPT carries higher reliance on partnership-driven revenue, while GH faces competitive intensity in the oncology diagnostics market.
- Tickeron's AI-driven analysis currently identifies one of these stocks as having a more favorable near-term trend structure based on technical and fundamental signals.
Introduction
Investors evaluating opportunities in the precision diagnostics sector often encounter two prominent names: Adaptive Biotechnologies and Guardant Health. Both companies harness advanced biological data and machine learning to address unmet medical needs, yet they pursue distinctly different market strategies. ADPT focuses on leveraging the adaptive immune system for disease detection and drug development, while GH has built its reputation on non-invasive cancer testing through blood-based liquid biopsies. This comparison is particularly relevant for traders and investors who follow healthcare innovation, diagnostic technology, or growth-stage biotech, where differences in business model execution, revenue trajectory, and market sentiment can create meaningful divergence in relative performance.
ADPT Overview and Recent Performance
ADPT, headquartered in Seattle, Washington, operates a commercial-stage biotechnology platform that decodes the adaptive immune system to develop clinical diagnostics and accelerate drug discovery. The company's core offerings include its ClonoSeq test for MRD monitoring in blood cancers and its T-cell receptor-based diagnostic and therapeutic discovery capabilities. In recent weeks, market activity surrounding ADPT has reflected cautious optimism tied to its partnership with Genentech and progress in expanding clinical utility data for its MRD business. Revenue growth has been steady but measured, and the company's cash runway has drawn investor attention as it balances investment in its immunoSEQ research platform against a path toward profitability. Broader sentiment toward the stock has been influenced by developments in the immunology and cell therapy spaces, where Adaptive's technology holds long-term strategic relevance.
GH Overview and Recent Performance
GH, based in Palo Alto, California, is a leading precision oncology company specializing in blood-based genomic testing for advanced and early-stage cancers. Its flagship Guardant360 test is widely used by oncologists for comprehensive genomic profiling of late-stage cancer patients, and the company's Shield test for colorectal cancer screening has been a focal point of recent investor attention following regulatory milestones. In recent trading weeks, GH has shown relative strength compared to peers in the diagnostics sector, supported by growing clinical adoption, favorable reimbursement trends, and expansion into screening markets that substantially broaden its addressable population. Revenue has continued to climb, and management commentary regarding test volume growth and average selling prices has generally been constructive. However, competition from other liquid biopsy companies and lingering questions about the pace of screening-market adoption remain key factors informing market positioning.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of algorithmic trading bots that have demonstrated strong alignment with current market conditions. With hundreds of AI-powered trading bots available on the platform, covering thousands of different tickers, only a subset earns placement in this featured section at any given time. These bots employ diverse trading styles—ranging from trend-following and swing trading to mean-reversion and breakout strategies—across multiple timeframes. Performance metrics vary by bot, with some achieving annualized returns above 20% and win rates exceeding 60%, depending on strategy type and market regime. Each bot operates with a distinct set of statistics, including trade frequency, average holding period, maximum drawdown, and Sharpe ratio (a measure of risk-adjusted return). Traders interested in systematic approaches to stock selection can explore the Trending AI Robots page to identify bots that match their risk tolerance and trading objectives.
Head-to-Head Comparison
At the business-model level, the two companies diverge in important ways. GH operates with a product-focused, high-volume diagnostic testing model that generates recurring clinical revenue from oncologists and, increasingly, from screening populations. ADPT, by contrast, blends clinical diagnostics with a drug-discovery platform that monetizes through pharmaceutical partnerships—a model that can yield milestone payments and royalties but is inherently less predictable quarter to quarter. On growth drivers, GH benefits from expanding indications, guideline inclusion, and screening-market penetration, while ADPT's catalysts center on MRD adoption in blood cancers and the advancement of T-cell-based therapeutics. Recent momentum has favored GH, which has shown stronger relative performance against benchmarks in the diagnostics group. Risk profiles differ as well: ADPT's partnership concentration and longer path to profitability introduce distinct uncertainty, whereas GH faces reimbursement pressure and intensifying competition. Sector exposure is another differentiator—GH is squarely in oncology diagnostics, while ADPT straddles immunology, infectious disease, and drug development. These contrasts offer traders a clear choice between a nearer-term commercial growth story and a longer-duration platform opportunity.
Tickeron AI Verdict
Based on observable trend signals and comparative positioning, Tickeron's AI-driven analysis would likely favor GH over ADPT in the current market environment. GH's more consistent revenue trajectory, clearer near-term catalysts in the cancer screening market, and relatively stronger technical trend structure suggest a higher probability of maintaining positive momentum. ADPT, while possessing a compelling long-term scientific platform, exhibits greater variability in its commercial milestones and a less linear path to value realization—factors that AI models typically penalize in shorter-horizon evaluations. This assessment reflects probabilistic analysis of trend consistency, relative stability, and catalyst visibility, rather than a definitive forecast. Traders should weigh these signals alongside their own research and time horizon preferences.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADPT is a Hold and GH is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ADPT’s FA Score shows that 0 FA rating(s) are green whileGH’s FA Score has 0 green FA rating(s).
- ADPT’s FA Score: 0 green, 5 red.
- GH’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ADPT’s TA Score shows that 3 TA indicator(s) are bullish while GH’s TA Score has 4 bullish TA indicator(s).
- ADPT’s TA Score: 3 bullish, 6 bearish.
- GH’s TA Score: 4 bullish, 4 bearish.
Price Growth
ADPT (@Medical Specialties) experienced а +1.35% price change this week, while GH (@Medical Specialties) price change was +9.95% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.40%. For the same industry, the average monthly price growth was -3.39%, and the average quarterly price growth was +6.80%.
Reported Earning Dates
ADPT is expected to report earnings on Nov 05, 2026.
GH is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Medical Specialties (+0.40% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| ADPT | GH | ADPT / GH | |
| Capitalization | 3.59B | 21.7B | 17% |
| EBITDA | -20.94M | -411.19M | 5% |
| Gain YTD | 38.978 | 58.596 | 67% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 295M | 1.18B | 25% |
| Total Cash | 218M | 1.05B | 21% |
| Total Debt | 77.6M | 1.7B | 5% |
ADPT | GH | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 82 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 47 Fair valued | 65 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 79 | |
SMR RATING 1..100 | 98 | 100 | |
PRICE GROWTH RATING 1..100 | 36 | 34 | |
P/E GROWTH RATING 1..100 | 100 | 100 | |
SEASONALITY SCORE 1..100 | 36 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ADPT's Valuation (47) in the Hospital Or Nursing Management industry is in the same range as GH (65) in the Medical Or Nursing Services industry. This means that ADPT’s stock grew similarly to GH’s over the last 12 months.
GH's Profit vs Risk Rating (79) in the Medical Or Nursing Services industry is in the same range as ADPT (100) in the Hospital Or Nursing Management industry. This means that GH’s stock grew similarly to ADPT’s over the last 12 months.
ADPT's SMR Rating (98) in the Hospital Or Nursing Management industry is in the same range as GH (100) in the Medical Or Nursing Services industry. This means that ADPT’s stock grew similarly to GH’s over the last 12 months.
GH's Price Growth Rating (34) in the Medical Or Nursing Services industry is in the same range as ADPT (36) in the Hospital Or Nursing Management industry. This means that GH’s stock grew similarly to ADPT’s over the last 12 months.
GH's P/E Growth Rating (100) in the Medical Or Nursing Services industry is in the same range as ADPT (100) in the Hospital Or Nursing Management industry. This means that GH’s stock grew similarly to ADPT’s over the last 12 months.
| ADPT | GH | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 90% | 3 days ago 81% |
| Stochastic ODDS (%) | 3 days ago 85% | 3 days ago 87% |
| Momentum ODDS (%) | 3 days ago 83% | 3 days ago 85% |
| MACD ODDS (%) | 3 days ago 80% | 3 days ago 73% |
| TrendWeek ODDS (%) | 3 days ago 83% | 3 days ago 80% |
| TrendMonth ODDS (%) | 3 days ago 82% | 3 days ago 82% |
| Advances ODDS (%) | 4 days ago 83% | 3 days ago 82% |
| Declines ODDS (%) | 21 days ago 86% | 6 days ago 85% |
| BollingerBands ODDS (%) | 3 days ago 84% | 3 days ago 79% |
| Aroon ODDS (%) | 3 days ago 82% | 3 days ago 86% |
Advertisement
GH and
Correlation & Price change
A.I.dvisor indicates that over the last year, GH has been loosely correlated with NTRA. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if GH jumps, then NTRA could also see price increases.